IDNEWSNOW.COM, Jakarta – The Food and Drugs Monitoring Company (BPOM) has actually provided an emergency situation use authorization (EUA) for the Zifivax Covid-19 vaccine on Thursday, October 7,2021
” Results from the stage 1, 2, and 3 clinical trials of Zifivax vaccines led to 81.71 percent efficacy seven days after complete vaccination,” stated BPOM chairperson Cent Lukito in an interview on Thursday, October 7,2021
Topics will be given 3 dosages of the vaccine through intramuscular injections within one month with 0.5 ml of the vaccine in each shot.
In dealing with the brand-new Covid-19 variations, according to Cent Lukito, Zifivax produced 92.93 percent efficacy against the Alpha version, 100 percent versus Gamma, 77.47 percent against Delta, and 90 percent versus Kappa version.
Negative effects caused by the vaccine’s injection are thought about to be under tolerable levels such as muscle discomfort in the location of injection, headaches, and fever. The vaccines can be saved under 2 to 4 degrees Celsius temperature, which the BPOM chief said fits a tropical nation such as Indonesia. Zifivax was established by Chinese firm Anhui Zhifei Longcom Biopharmaceutical.
SYAHARANI PUTRI
